Browse by Poster Presenter

Type here to filter the list

G
Gómez-Pérez, Beatriz

"La Arrixaca" Clinical University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
Beatriz Gómez-Pérez
Favorite
(P 078) GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
Beatriz Gómez-Pérez
Favorite
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Beatriz Gómez-Pérez
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Beatriz Gómez-Pérez
Favorite
Gaiero, Leticia

Unidad de Patología Oncológica Musculo Esquelética, Instituto Nacional de Ortopedia y Traumatología
(P 077) FREEZING IN FLORIDA: ARE WE READY FOR DIVERSITY?
Leticia Gaiero
Favorite
(P 309) THE ONCOLOGY ORTHOPEDIST ROLE: WHERE DO WE FIT?
Leticia Gaiero
Favorite
Gainor, Justin

Massachusetts General Hospital
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Justin Gainor
Favorite
Gai, Xiaowu

Children's Hospital Los Angeles
(P 045) DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Xiaowu Gai
Favorite
Gajda, Margaret

University of Pittsburgh Medical Center
(P 087) RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Margaret Gajda
Favorite
Galiano, Antonella

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Antonella Galiano
Favorite
Gálvez-Montosa, Fernando

Hospital Universitario de Jaén
(P 083) PERFORMANCE OF THE MESENCHYMAL TUMOR COMMITTEE IN A SMALL HOSPITAL IN SOUTHERN SPAIN
Fernando Gálvez-Montosa
Favorite
Gambarotti, Marco

Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Marco Gambarotti
Favorite
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Marco Gambarotti
Favorite
Gandra, Divya

Atrium Health - Levine Children's Hospital
(P 246) PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Divya Gandra
Favorite
Gan, Hao Wen Gerald

Beatson West of Scotland Cancer Centre
(P 073) EVALUATING DISTRESS AND THE PATIENT EXPERIENCE OF SARCOMA PATIENTS IN THE WEST OF SCOTLAND
Hao Wen Gerald Gan
Favorite
Ganjoo, Kristen

Stanford Cancer Center, Stanford University
(P 047) FEASIBILITY OF A PERSONALIZED AND TUMOR-INFORMED CT-DNA ASSAY IN PATIENTS WITH LEIOMYOSARCOMA
Kristen Ganjoo
Favorite
(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Kristen Ganjoo
Favorite
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Kristen Ganjoo
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Kristen Ganjoo
Favorite
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Kristen Ganjoo
Favorite
Gao, Dongxia

University of British Columbia
(P 129) MATURE DENDRITIC CELLS ON TISSUE MICROARRAY CORES CORRELATE WITH THE PRESENCE OF ADJACENT TERTIARY LYMPHOID STRUCTURES IN EPITHELIOID SARCOMA
Dongxia Gao
Favorite
Gao, Junheng

Duke
(P 034) REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Junheng Gao
Favorite
Garbitt-Amaral, Victoria

Foghorn Therapeutics
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Victoria Garbitt-Amaral
Favorite
García de Quevedo Suero, Coral

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Coral García de Quevedo Suero
Favorite
García-Muñoz, Rubén

Hospital Universitario de Jaén
(P 083) PERFORMANCE OF THE MESENCHYMAL TUMOR COMMITTEE IN A SMALL HOSPITAL IN SOUTHERN SPAIN
Rubén García-Muñoz
Favorite
Garcia, Gabriel

Hospital insular gran canaria
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Gabriel Garcia
Favorite
García-Ortega, Dorian Yarih

Department of skin, soft-tissue & bone tumors, National Cancer Institute (México)
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Dorian Yarih García-Ortega
Favorite
Garolla, Andrea

University of Padova
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Andrea Garolla
Favorite
Garralda, Elena

Vall d’Hebron Institute of Oncology
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Elena Garralda
Favorite
Garrido-López, Pilar

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Pilar Garrido-López
Favorite
Gartrell, Jessica

St. Jude Children’s Research Hospital
(P 012) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Jessica Gartrell
Favorite
Garzia, Livia

Department of Orthopaedic Surgery, McGill University
(P 022) EZHIP ECTOPIC EXPRESSION AND ITS ROLE IN OSTEOSARCOMA PATHOGENESIS
Livia Garzia
Favorite
(P 030) OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Livia Garzia
Favorite
(P 232) DECIPHERING METASTASIS MAINTENANCE AND CHEMO RESISTANCE EVENTS IN CIC-DUX4 SARCOMA
Livia Garzia
Favorite
Garzone, Sammi

Cleveland Clinic
(P 311) VIRTUAL VISITS FOR SARCOMAS AND OTHER RARE CANCERS INCLUDING DESMOIDS: THE EVOLUTION OF INFORMATION AND EDUCATIONAL OPPORTUNITIES TO IMPOVE HEALTH: 2017-2022
Sammi Garzone
Favorite
Gasparini, Patrizia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Patrizia Gasparini
Favorite
Gaspar, Nathalie

Gustave Roussy
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Nathalie Gaspar
Favorite
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Nathalie Gaspar
Favorite
(P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Nathalie Gaspar
Favorite
Gasparro, Matthew

Chicago Medical School
(P 273) 3D-PRINTED PATIENT-SPECIFIC CUTTING GUIDES VERSUS FREEHAND RESECTION FOR INTERNAL HEMIPELVECTOMY: CLINICAL AND ONCOLOGIC OUTCOMES
Matthew Gasparro
Favorite
(P 287) INTERNAL HEMIPELVECTOMY: A SINGLE INSTITUTION'S LEARNING CURVE AND LONGITUDINAL EXPERIENCE
Matthew Gasparro
Favorite
Gauduchon, Thibault

CENTRE LEON BERARD
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Thibault Gauduchon
Favorite
Gaunt, Piers

University of Birmingham
(P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Piers Gaunt
Favorite
Gelderblom, Hans

Leiden University Medical Center, Leiden, Netherlands
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Hans Gelderblom
Favorite
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Hans Gelderblom
Favorite
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Hans Gelderblom
Favorite
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Hans Gelderblom
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Hans Gelderblom
Favorite
(P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Hans Gelderblom
Favorite
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Hans Gelderblom
Favorite
genestie, catherine

CLCC gustave roussy
(P 048) IMMUNE INFILTRATION AS PROGNOSTIC FACTORS IN METASTATIC LEIOMYOSARCOMA
catherine genestie
Favorite
(P 060) TOWARD A NEW GENOMIC AND CLINICO-PATHOLOGIC CLASSIFICATION OF UTERINE ADENOSARCOMAS
catherine genestie
Favorite
Geng, Junxian

Boehringer Ingelheim Pharmaceuticals, Inc.
(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Junxian Geng
Favorite
Gennaro, Nicolò

Istituto di Imaging della Svizzera Italiana (IIMSI) Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Nicolò Gennaro
Favorite
Gennatas, Spyridon

Guy's and St Thomas' NHS Foundation Trust
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Spyridon Gennatas
Favorite
Gentet, Jean-Claude

AP HM
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Jean-Claude Gentet
Favorite
George, Suzanne

Dana-Farber Cancer Institute
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Suzanne George
Favorite
(P 143) A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Suzanne George
Favorite
(P 214) EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Suzanne George
Favorite
(P 316) FIRST-IN-HUMAN PHASE 1/1B STUDY OF IDRX-42, A NOVEL ORAL TYROSINE KINASE KIT INHIBITOR, IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS
Suzanne George
Favorite
Gerber, Nicolas

University Children's Hospital
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Nicolas Gerber
Favorite
Gerger, Armin

Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Armin Gerger
Favorite
Gerstle, J. Ted

Memorial Sloan Kettering Cancer Centre
(P 124) EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
J. Ted Gerstle
Favorite
Gervais, MaiKim

Hopital Maisonneuve-Rosemont
(P 088) RETHINKING THE MANAGEMENT OF AGGRESSIVE ANGIOMYXOMA: A REPORT FROM FOUR CANADIAN SARCOMA CENTRES.
MaiKim Gervais
Favorite
Ghert, Michelle

McMaster University
(P 075) EXAMINING PATIENT PERSPECTIVES ON SARCOMA SURVEILLANCE: THE SARCOMA SURVEILLANCE SURVEY
Michelle Ghert
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Michelle Ghert
Favorite
Ghia, Amol

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Amol Ghia
Favorite
GHIGNA, MARIA ROSA

INSTITUT GUSTAVE ROUSSY
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
MARIA ROSA GHIGNA
Favorite
Gilbert, Ralph

Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Ralph Gilbert
Favorite
Gil, Elena

“La Arrixaca” Clinical University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
Elena Gil
Favorite
(P 078) GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
Elena Gil
Favorite
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Elena Gil
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Elena Gil
Favorite
Gil-Vazquez, Pedro J

"La Arrixaca" Clinical University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
Pedro J Gil-Vazquez
Favorite
(P 078) GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
Pedro J Gil-Vazquez
Favorite
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Pedro J Gil-Vazquez
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Pedro J Gil-Vazquez
Favorite
Giordano, Laura

Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Laura Giordano
Favorite
(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Laura Giordano
Favorite
Gitelis, Steven

Rush University Medical Center
(P 053) PET-CT STAGING AFFECTS TIME TO TREATMENT IN SARCOMA
Steven Gitelis
Favorite
(P 062) WHAT IS THE CLINICAL IMPACT OF STAGING AND SURVEILLANCE PET-CT SCAN FINDINGS IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA?
Steven Gitelis
Favorite
(P 081) MISSING DATA IN THE DEVELOPMENT AND EXTERNAL VALIDATION OF MACHINE LEARNING MODELS FOR SURVIVAL PREDICTION IN SARCOMA
Steven Gitelis
Favorite
(P 086) RADIOTHERAPY, VOLUME REDUCTION, AND SHORT-TERM SURGICAL OUTCOMES IN THE TREATMENT OF LARGE MYXOID LIPOSARCOMAS
Steven Gitelis
Favorite
(P 094) TOTAL KNEE ARTHROPLASTY FOR OSTEOARTHRITIS IS UNCOMMON AFTER INTRALESIONAL CURETTAGE IN GIANT CELL TUMOR OF BONE
Steven Gitelis
Favorite
(P 206) RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Steven Gitelis
Favorite
(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Steven Gitelis
Favorite
(P 273) 3D-PRINTED PATIENT-SPECIFIC CUTTING GUIDES VERSUS FREEHAND RESECTION FOR INTERNAL HEMIPELVECTOMY: CLINICAL AND ONCOLOGIC OUTCOMES
Steven Gitelis
Favorite
(P 277) BEARING SELECTION IN PROXIMAL FEMORAL REPLACEMENT: A COMPARISON OF CLINICAL OUTCOMES
Steven Gitelis
Favorite
(P 283) HIP ARTHROPLASTY OUTCOMES IN METASTATIC BONE DISEASE
Steven Gitelis
Favorite
(P 287) INTERNAL HEMIPELVECTOMY: A SINGLE INSTITUTION'S LEARNING CURVE AND LONGITUDINAL EXPERIENCE
Steven Gitelis
Favorite
(P 295) PERIACETABULAR INTERNAL HEMIPELVECTOMY WITH AND WITHOUT SACRAL RESECTION: AN INSTITUTIONAL EXPERIENCE AND SYSTEMATIC REVIEW
Steven Gitelis
Favorite
Giudici, Fabiola

CLCC gustave roussy
(P 048) IMMUNE INFILTRATION AS PROGNOSTIC FACTORS IN METASTATIC LEIOMYOSARCOMA
Fabiola Giudici
Favorite
Gladdy, Rebecca

Lunenfeld Tanenbaum Research Institute
(P 05) GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Rebecca Gladdy
Favorite
Gladdy, Rebecca

Department of Surgery, Mount Sinai Hospital; Department of Surgery, University of Toronto; Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Rebecca Gladdy
Favorite
Gladdy, Rebecca

Lunenfeld Tanenbaum Research Institute
(P 124) EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Rebecca Gladdy
Favorite
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Rebecca Gladdy
Favorite
(P 190) SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA
Rebecca Gladdy
Favorite
(P 191) SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Rebecca Gladdy
Favorite
Gladdy, Rebecca

Department of Surgery, Mount Sinai Hospital; Department of Surgery, University of Toronto; Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Rebecca Gladdy
Favorite
Glade Bender, Julia

Memorial Sloan Kettering Cancer Center
(P 04) EXPERT PANEL REVIEW OF THE PRO-AYA: PARTIENT-REPORTED OUTCOMES FOR ADOLESCENTS AND YOUNG ADULTS WITH CANCER
Julia Glade Bender
Favorite
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Julia Glade Bender
Favorite
(P 307) ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA
Julia Glade Bender
Favorite
Glaspell, Andrea

Nationwide Children’s Hospital
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Andrea Glaspell
Favorite
Glaspy, John

UCLA
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
John Glaspy
Favorite
Glimm, Hanno

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ)
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Hanno Glimm
Favorite
Goda, Mark

Department of Orthopaedics and Trauma, Medical University of Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Mark Goda
Favorite
Gokgoz, Nalan

Lunenfeld-Tanenbaum Research Institute
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Nalan Gokgoz
Favorite
(P 233) DETERMINING THE CONTRIBUTIONS OF PD-L1 AND STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Nalan Gokgoz
Favorite
Golafshar, Michael

Department of Qualitative Health Sciences, Section of Biostatistics, Mayo Clinic
(P 202) LONG-TERM EXPERIENCE WITH INTRAOPERATIVE ELECTRON RADIATION THERAPY BOOST IN EXTREMITY SARCOMA
Michael Golafshar
Favorite
Goldaracena, Isabel

Wyss Institute for Biologically Inspired Engineering, Harvard University
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Isabel Goldaracena
Favorite
Goldenburg, Neil

Johns Hopkins All Children's Hospital
(P 305) THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Neil Goldenburg
Favorite
Goldsmith, Riley

College of Medicine Tucson
(P 208) STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PEDIATRIC OSTEOSARCOMA LUNG METASTASES
Riley Goldsmith
Favorite
Goldstein, David

Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
David Goldstein
Favorite
Golik, Paweł

Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland & Institute of Biochemistry and Biophysics Polish Academy of Science, Warsaw, Poland
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Paweł Golik
Favorite
Go, Lise

Monopar Therapeutics, Inc.
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Lise Go
Favorite
Gomeniouk, Olga

Rush University Medical Center
(P 018) COMPLETE RESPONSE TO MODEST DOSE RADIATION IN OSTEOSARCOMA METASTASIS IN TWO PATIENTS WITH LI-FRAUMENI SYNDROME
Olga Gomeniouk
Favorite
Goncalves, Priscila

Regeneron Pharmaceuticals
(P 131) MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Priscila Goncalves
Favorite
Gong, Amanda

College of Medicine Tucson
(P 208) STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PEDIATRIC OSTEOSARCOMA LUNG METASTASES
Amanda Gong
Favorite
Gong, Matthew

University of Pittsburgh Medical Center
(P 046) EVALUATION OF INTRAOPERATIVE TUMOR MARGINS IN SARCOMA WITH FLUORESCENT DYE IMAGING: A PRELIMINARY ANALYSIS OF RESULTS
Matthew Gong
Favorite
González, Jose Antonio

Hospital de La Santa Creu I Sant Pau
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Jose Antonio González
Favorite
Gordon, Erlinda Maria

Sarcoma Oncology Research Center
(P 122) AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Erlinda Maria Gordon
Favorite
(P 123) COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)
Erlinda Maria Gordon
Favorite
(P 126) GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Erlinda Maria Gordon
Favorite
(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Erlinda Maria Gordon
Favorite
(P 133) PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]
Erlinda Maria Gordon
Favorite
(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Erlinda Maria Gordon
Favorite
(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Erlinda Maria Gordon
Favorite
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Erlinda Maria Gordon
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Erlinda Maria Gordon
Favorite
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Erlinda Maria Gordon
Favorite
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Erlinda Maria Gordon
Favorite
Gordon, Gary

Ayala Pharmaceuticals
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Gary Gordon
Favorite
Gouin, Francois

Centre Léon Bérard, Lyon, France
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Francois Gouin
Favorite
Goulding, Krista

Department of Orthopedic Surgery, Mayo Clinic
(P 064) A SYSTEMATIC REVIEW OF PATIENT-REPORTED OUTCOMES USED TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN SOFT-TISSUE SARCOMA
Krista Goulding
Favorite
(P 082) PATIENT-REPORTED OUTCOME MEASURES TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH SOFT-TISSUE SARCOMA: A SYSTEMATIC REVIEW OF MEASUREMENT PROPERTIES OF PATIENT-REPORTED OUTCOMES
Krista Goulding
Favorite
(P 092) THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Krista Goulding
Favorite
(P 202) LONG-TERM EXPERIENCE WITH INTRAOPERATIVE ELECTRON RADIATION THERAPY BOOST IN EXTREMITY SARCOMA
Krista Goulding
Favorite
Gounder, Mrinal

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Mrinal Gounder
Favorite
(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Mrinal Gounder
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Mrinal Gounder
Favorite
Govindan, Ramaswamy

Washington University School of Medicine
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Ramaswamy Govindan
Favorite
Goytain, Angela

UBC
(P 050) MULTIPLEX DETECTION OF TRANSLOCATION ASSOCIATED SARCOMAS WITH COMBINED FUSION JUNCTION SPANNING PROBES AND EXON IMBALANCE ANALYSIS
Angela Goytain
Favorite
Gröschel, Stefan

German Cancer Research Center
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Stefan Gröschel
Favorite
Grüneisen, Johannes

Institute of Radiology, University Duisburg-Essen, Medical School, Essen, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Johannes Grüneisen
Favorite
Grünhagen, Dirk

Erasmus Medical Center
(P 044) AUTOMATIC SEGMENTATION USING DEEP LEARNING TO DISTINGUISH BETWEEN 9 TYPES OF SOFT-TISSUE TUMORS WITH RADIOMICS
Dirk Grünhagen
Favorite
(P 051) NON-INVASIVE DETECTION OF SOFT TISSUE SARCOMA USING VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH: A PILOT STUDY
Dirk Grünhagen
Favorite
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Dirk Grünhagen
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Dirk Grünhagen
Favorite
Graadt van Roggen, Frans

Department of Pathology, Leiden University Medical Center
(P 109) NOVEL CANDIDATE BIOMARKERS FOR FLUORESCENCE IMAGE-GUIDED SURGERY IN GASTROINTESTINAL STROMAL TUMORS
Frans Graadt van Roggen
Favorite
Graham, Ann

MIB Agents Osteosarcoma
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Ann Graham
Favorite
Grams, Michael

Mayo Clinic
(P 207) SPATIALLY FRACTIONATED RADIATION THERAPY IN SARCOMAS: THE MAYO CLINIC EXPERIENCE
Michael Grams
Favorite
Granegger, Barbara

Department of Orthopaedics and Trauma, Medical University of Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Barbara Granegger
Favorite
Graves, Laurie

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Duke University
(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Laurie Graves
Favorite
Grbovic-Huezo, Olivera

MSKCC
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Olivera Grbovic-Huezo
Favorite
Greco, Stephanie

Fox Chase Cancer Center
(P 221) SURGICAL OUTCOMES OF NEOADJUVANT THERAPY FOR GASTROINTESTINAL STROMAL TUMORS: A SINGLE INSTITUTION ANALYSIS
Stephanie Greco
Favorite
Green, Angela

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Angela Green
Favorite
Greto, Daniela

Department of Radiotherapy, Azienda Ospedaliero Universitaria Careggi, Univerisity of Florence, Florence, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Daniela Greto
Favorite
Grieco, Mariachiara

Department of Biosciences, University of Milan and Italian Institute for Genomic Medicine (Candiolo, Turin))
(P 029) MOLECULAR CHARACTERIZATION OF OSTEOSARCOMA AND EWING SARCOMA IN PEDIATRIC PATIENTS REVEALS NOVEL RNA-BASED INTERVENTION POINTS.
Mariachiara Grieco
Favorite
Griffin, Anthony

Mount Sinai Hospital
(P 059) SURGICAL MANAGEMENT OF CHONDROSARCOMA OF LONG BONES UTILIZING A PRE-OPERATIVE RADIOLOGIC AGGRESSIVENESS SCORE?
Anthony Griffin
Favorite
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Anthony Griffin
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Anthony Griffin
Favorite
(P 304) SURGICAL STAGING OF OSTEOSARCOMA: WHAT IS THE OPTIMAL METHOD FOR PREDICTING LOCAL RECURRENCE?
Anthony Griffin
Favorite
Griffin, Katherine

University of California, Davis
(P 175) FIBRIN-ALGINATE INTERPENETRATING NETWORK HYDROGELS AS BIOMIMETIC PLATFORMS TO STUDY OSTEOSARCOMA
Katherine Griffin
Favorite
Grignani, Giovanni

Department of Medical Oncology-Sarcoma Unit, Candiolo Cancer Institute FPO-IRCCS, Candiolo (TO), Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Giovanni Grignani
Favorite
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Giovanni Grignani
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Giovanni Grignani
Favorite
Grignol, Valerie

The Ohio State University Comprehensive Cancer Center
(P 259) ASSOCIATION BETWEEN AREA DEPRIVATION INDEX AND INITIAL TREATMENT AMONG PATIENTS WITH DESMOID TUMORS
Valerie Grignol
Favorite
Grimaudo, Maria Susanna

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Maria Susanna Grimaudo
Favorite
(P 08) HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Maria Susanna Grimaudo
Favorite
Grimaudo, Maria Susanna

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, 20089, Italy
(P 117) SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Maria Susanna Grimaudo
Favorite
Grimaudo, Maria Susanna

Humanitas Research Hospital
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Maria Susanna Grimaudo
Favorite
Grimaudo, Maria Susanna

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, 20089, Italy
(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Maria Susanna Grimaudo
Favorite
Grimison, Peter

Chris O'Brien Lifehouse
(P 149) CHARACTERISTICS OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS REFERRED TO A DEDICATED EARLY PHASE CLINICAL TRIAL CLINIC
Peter Grimison
Favorite
(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE
Peter Grimison
Favorite
Grizzi, Fabio

Humanitas Research Hospital
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Fabio Grizzi
Favorite
Grohar, Patrick

Children’s Hospital of Philadelphia
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Patrick Grohar
Favorite
Gromova, Elena

Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
(P 158) NEOADJUVANT COMBINATION OF DOXORUBICIN, CISPLATIN AND METHOTREXATE IN PATIENTS AGED 24-40 YEARS WITH OSTEOSARCOMA UNDER THE COVERAGE OF HEMODIALYSIS. AMAP2021-7-2. ONGOING TRIAL
Elena Gromova
Favorite
Gronchi, Alessandro

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Alessandro Gronchi
Favorite
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Alessandro Gronchi
Favorite
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Alessandro Gronchi
Favorite
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Alessandro Gronchi
Favorite
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Alessandro Gronchi
Favorite
(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Alessandro Gronchi
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Alessandro Gronchi
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Alessandro Gronchi
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Alessandro Gronchi
Favorite
Gross, Amy

Center for Childhood Cancer, Nationwide Children's Hospital
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Amy Gross
Favorite
Grosshans, David

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
David Grosshans
Favorite
Grossman, Julie

University of Miami
(P 098) COMBINATION THERAPY WITH IMATINIB AND PAC-1 INDUCES TREATMENT SYNERGISM IN GASTROINTESTINAL STROMAL TUMORS
Julie Grossman
Favorite
Groundland, John

Huntsman Cancer Institute
(P 306) THERMAL NECROSIS IN ORTHOPAEDIC BONE TUMORS
John Groundland
Favorite
Guan, Peiyong

Genome Institute of Singapore
(P 174) ESTABLISHMENT AND CHARACTERIZATION OF A PATIENT-DERIVED SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA CELL LINE MODEL
Peiyong Guan
Favorite
Guan, Zhaoming

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080
(P 101) CYTOREDUCTIVE SURGERY FOR METASTATIC GASTROINTESTINAL STROMAL TUMORS TREATED WITH RIPRETINIB: A SINGLE-CENTER ANALYSIS.
Zhaoming Guan
Favorite
Guidos, Cynthia

Hospital for Sick Children Research Institute
(P 124) EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Cynthia Guidos
Favorite
Guillén, María José

Research Department, PharmaMar S.A.
(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
María José Guillén
Favorite
Guilloteau, Florent

Hôpital Maisonneuve-Rosemont
(P 049) IMPLEMENTATION OF A ROUTINE DIAGNOSTIC NEXT GENERATION SEQUENCING PANEL OF FUSION-POSITIVE SARCOMAS: A SINGLE CENTER EXPERIENCE
Florent Guilloteau
Favorite
Gullane, , Patrick

Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
, Patrick Gullane
Favorite
Gundavda, Manit

Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
(P 059) SURGICAL MANAGEMENT OF CHONDROSARCOMA OF LONG BONES UTILIZING A PRE-OPERATIVE RADIOLOGIC AGGRESSIVENESS SCORE?
Manit Gundavda
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Manit Gundavda
Favorite
Gundavda, Manit

Mount SInai Hospital/University of Toronto
(P 304) SURGICAL STAGING OF OSTEOSARCOMA: WHAT IS THE OPTIMAL METHOD FOR PREDICTING LOCAL RECURRENCE?
Manit Gundavda
Favorite
Guo, Qiuxiang

Abbisko Therapeutics
(P 164) PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE
Qiuxiang Guo
Favorite
Guo, Wei

Peking University People’s Hospital
(P 021) DISTINCT GENOMIC FEATURES BETWEEN OSTEOSARCOMAS FIRSTLY METASTASING TO BONE AND TO LUNG
Wei Guo
Favorite
Gupta, Abha

Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Ontario, Canada; Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada; CanSaRCC, Princess Margaret Cancer Center, Ontario, Canada
(P 05) GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Abha Gupta
Favorite
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abha Gupta
Favorite
(P 124) EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Abha Gupta
Favorite
Gupta, Abha

Princess Margaret Cancer Centre, Hospital for Sick Children, AYA, CanSaRCC
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Abha Gupta
Favorite
Gupta, Abha

Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Ontario, Canada; Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada; CanSaRCC, Princess Margaret Cancer Center, Ontario, Canada
(P 190) SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA
Abha Gupta
Favorite
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Abha Gupta
Favorite
Gupta, Hersh

Dana-Farber Cancer Institute
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Hersh Gupta
Favorite
Gupta, Sudeep

Tata Memorial Centre
(P 03) DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Sudeep Gupta
Favorite
Guram, Sheena

The Institute of Cancer Research
(P 05) GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Sheena Guram
Favorite
Gurrieri, Lorena

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Lorena Gurrieri
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Lorena Gurrieri
Favorite
Gusho, Charles

University of Missouri
(P 273) 3D-PRINTED PATIENT-SPECIFIC CUTTING GUIDES VERSUS FREEHAND RESECTION FOR INTERNAL HEMIPELVECTOMY: CLINICAL AND ONCOLOGIC OUTCOMES
Charles Gusho
Favorite
Gutiérrez Fernández, Ana Isabel

“La Arrixaca” university hospital
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Ana Isabel Gutiérrez Fernández
Favorite
Gutierrez, Antonio

University Hospital Son Espases,
(P 113) PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY
Antonio Gutierrez
Favorite
Gutierrez, Antonio

HU Son Espases
(P 135) PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Antonio Gutierrez
Favorite
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Antonio Gutierrez
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Antonio Gutierrez
Favorite
Guzzo, Marco

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Marco Guzzo
Favorite
Gygi, Steven P.

Harvard Medical School
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Steven P. Gygi
Favorite
Gyorki, David

Peter MacCallum Cancer Centre
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
David Gyorki
Favorite